Case Report

An unusual presentation of a severely calcified subserous leiomyoma in a postmenopausal woman: a case report

Sunil Kumar Samal*, Setu Rathod, Reddi Rani, R. Anandraj

INTRODUCTION

Uterine fibroids constitute one of the most ubiquitous benign tumours encountered by gynaecologist all over the world which composed mainly of smooth muscle cells and varying amounts of fibrous tissue. An incidence of 20-50% is frequently quoted by various authors and histopathology studies of hysterectomy specimens. Postmenopausal shrinkage of fibroid occurs in 70-90% of the women and only few cases of postmenopausal severely calcified leiomyomas have been reported in the literature.

CASE REPORT

A 58-year-old postmenopausal lady presented to our department with mass descending per vaginum and occasional lower abdominal pain since one year. She is P2L2, all full term normal delivery, last child birth 25 years back and was ligated. The patient had regular menstruation from menarche (12 years) to menopause (48 years), and never took hormone replacement therapy. General and systemic examination revealed no abnormality. On local examination there was second stage utero-vaginal prolapse according to Pelvic organ prolapsed quantification (POP-Q) system which was reducible. Per examination revealed retroverted bulky uterus and one hard mobile mass of size 6x6 cm in the pouch of Douglas. A provisional diagnosis of posterior subserosal calcifying leiomyoma was made with a differential diagnosis of a solid fibrotic ovarian tumour. All standard laboratory tests were within normal range including the CA-125, which was 14.2 U/mL. Pelvic ultrasound revealed posterior subserosal fibroid. A kidney, ureter, and bladder x-ray (KUB) (Figure 1) showed a severely calcified mass in the pelvic cavity suggestive of a calcified leiomyoma. Final diagnosis of second stage utero-vaginal prolapse with posterior subserosal calcified leiomyoma was made and the patient was planned for vaginal hysterectomy with pelvic floor repair. Apart from this consent was also taken for laparotomy and abdominal hysterectomy if required. Vaginal hysterectomy with pelvic floor repair was done and the myoma was found to be FIGO class 6. On gross examination, a hard mass of size 6x6 cm with the
exposed surface containing smooth muscle, adipose tissue and bony fragments (Figure 2). Histopathological examination after fixation and decalcification confirmed the diagnosis of leiomyoma by hyalinization and dystrophic calcification. The patient was discharged four days after the surgery and on follow-up, there were no further problems noted.

**DISCUSSION**

Leiomyomas are rarely found in postmenopausal women because their growth is thought to be estrogen dependent and most of them regress after menopause. As leiomyomas enlarge, they may outgrow their blood supply, resulting in various types of degeneration: hyaline or myxoid degeneration, calcification, cystic degeneration, or red degeneration. In general, hyaline degeneration is the most common (63%) form of degeneration, while the others occur less frequently, such as myxomatous changes (13%), calcification (8%), mucoid changes (6%), cystic degeneration (4%), red degeneration (3%), and fatty changes (3%). Calcified degeneration commonly seen in menopausal age group, black women and in women who have pedunculated subserous tumour. They become radioopaque due to the presence of calcium in them and so they are known as “Wombstones”.

Although most of fibroids regress after menopause, there are a few reported cases of leiomyoma growth in postmenopausal women. Kawamura et al. suggested that other estrogens or growth factors, such as estrone, Insulin-Like Growth Factors (IGF), or Epidermal Growth Factors (EGF), might play a role in the growth of leiomyomas in postmenopausal women. Lumsden et al. and Vollenhoven et al. suggested that an association of polypeptide growth factors such as Platelet Derived Growth Factors (PDGF), transforming growth factors, and Vascular Endothelial Growth Factors (VEGF), stimulated the growth of leiomyomas. Many of these growth factors are overexpressed in leiomyomas and either increase smooth muscle proliferation (TGF - transforming growth factor, FGF - fibroblast growth factors) or DNA synthesis (EGF, PDGF), stimulate synthesis of extracellular matrix (TGF-β), and promote mitogenesis (TGF-β, EGF, IGF, prolactin), or angiogenesis (FGF, VEGF). If a postmenopausal woman is obese, peripheral conversion of adrenal derived androstenedione to estrone by aromatization of fat might stimulate the growth of leiomyomas.

Clinically significant subserous and intramural fibroids can usually be diagnosed by pelvic examination based on findings of an enlarged, irregularly shaped, firm and non-tender uterus. Routine sonographic examination is not necessary when the diagnosis is almost certain. However, a definite diagnosis of submucous fibroids often requires saline-infusion sonography, hysteroscopy, or magnetic resonance imaging. The FIGO fibroid classification system categorises submucosal, intramural, subserosal, and transmural fibroids (Table 1). According to this classification, our case was found to be of class 6.

### Table 1: FIGO leiomyoma classification system

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>SM-Submucosal</td>
<td>0 Pedunculated intracavitary</td>
</tr>
<tr>
<td></td>
<td>1 &lt;50% intramural</td>
</tr>
<tr>
<td></td>
<td>2 ≥50% intramural</td>
</tr>
<tr>
<td>O-Other</td>
<td>3 Contacts endometrium; 100% intramural</td>
</tr>
<tr>
<td></td>
<td>4 Intramural</td>
</tr>
<tr>
<td></td>
<td>5 Subserosal ≥50% intramural</td>
</tr>
<tr>
<td></td>
<td>6 Subserosal &lt;50% intramural</td>
</tr>
<tr>
<td></td>
<td>7 Subserosal pedunculated</td>
</tr>
<tr>
<td></td>
<td>8 Other (Specify e.g. cervical, parasitic)</td>
</tr>
</tbody>
</table>
| Hybrid leiomyomas | Two numbers are listed separately by a hyphen. By convention, the first refers to the relationship with the endometrium while the second refers to the relationship to the serosa. For example-
| impact both endometrium and serosa | Submucosal and subserosal, each with less than half the diameter in the endometrial and peritoneal cavities, respectively. |
Funding: No funding sources  
Conflict of interest: None declared  
Ethical approval: Not required

REFERENCES


DOI: 10.5455/2320-1770.ijrcog20140638  